There’s a small biotech company with big plans to play spoiler in a fight between Amgen and Regeneron Pharmaceuticals, and its cholesterol-lowering pill met its mark in the first of five studies that will determine its fate.

Esperion Therapeutics said Wednesday that its once-a-day pill, combined with the now-generic Zetia, lowered bad cholesterol by 28 percent more than the old drug alone, good enough to meet the trial’s primary goal. The study, involving 269 patients, is the smallest and shortest of the five Esperion expects to report this year. The largest, in which 3,000 patients will get either Esperion’s drug or placebo over the course of at least a year, is scheduled to read out in May.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy